Ghirardelli P, Franceschini D, D’Aveni A, et al. - Researchers conducted this retrospective analysis to determine the role of focal radiotherapy (FRT) as a therapeutic choice for oligo-progressive malignant pleural mesothelioma (MPM). This study involved consecutive patients pretreated with ≥ 1 lines of chemotherapy. Either stereotactic body radiotherapy (SBRT, ≥ 5 Gy per fraction) or hypo-fractionated radiotherapy (hypoRT, < 5 Gy per fraction) was administered to patients. The primary endpoints included time to further systemic therapy (TFST) and local control (LC) following FRT. The median TFST was estimated to be 6 months. At 6 months and 1 year, LC was 84% and 76%, respectively. Overall, findings revealed that in selected patients with oligo-progressive MPM, it was feasible to use FRT as a treatment option, which not only permitted delay of further systemic therapies but also did not result in severe toxicity. Results demonstrated greater effectiveness of FRT when performed at progression following one line of systemic therapy. A radio-resistant behavior of MPM was indicated.